Friday, 8 November 2013

DSM and Chemtrix sign collaboration agreement in Continuous Flow Chemistry

Image Courtesy: Chemtrix
DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM (NYSE, Euronext: DSM KON), announced today that it has signed a collaboration agreement with Chemtrix B.V., The Netherlands, in the field of Continuous Flow Chemistry to provide sustainable equipment and, development and manufacturing services to the pharmaceutical industry.

The agreement brings together the expertise of both parties in continuous flow chemistry to better serve the pharmaceutical industry with processes for the development and manufacture of active pharmaceutical ingredients (APIs), which require new technologies to increase sustainability, reduce energy consumption and provide benefits for cost-of-goods. Chemtrix’ specializes in ready-to-use laboratory and kilo-scale micro reactors, as well as reactor and process design for industrial reactors, which complement DSM’s proven track record in drug synthesis route development, scale-up and implementation of continuous flow processes for manufacturing. DSM achieved one of the first industrial scale, FDA approved uses of micro reactors for making a pharmaceutical at commercial scale under current Good Manufacturing Practices (cGMP) at their facility in Linz, Austria.

Initially the DSM-Chemtrix collaboration will offer an Industrial Flow Process Development package to clients, in order to provide tailor-made, scalable flow chemistry solutions. This package covers all phases of process design, from scanning chemistries, chemistry development, route scouting, equipment design and scale-up for fully continuous or integrated processes.